Fundraising FoxMerck Global Health Innovation Fund — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
ID Connect provides access to specialized infectious disease (ID) expertise through a team of clinicians and technology staff, using telemedicine to improve patient care and outcomes.
Digital HealthHealthtechMedical DevicesCranberry Township, US
John Mellors(Co-founder)Riaan Erwee(Executive Officer)Tami Minnier(Director)Rima Abdel-Massih(Co-founder)Brenton Burns(Director)Jonathan Phillips(Director)
Co-investorsMSD Global Health Innovation FundUPMC EnterprisesFirst Trust Capital Partners
Protillion Biosciences develops platform technology for antibody engineering and drug discovery.
AI & Machine LearningBiotechDeep TechCarlsbad, US
Curtis Layton(CEO/Co-Founder)inDavid Walt(Co-Founder)inWill Greenleaf(Co-Founder)inRobert Hollingsworth(Chief Scientific Officer)in
BoardSean Kendall(Director)inMalek Faham(Director)in
Co-investorsARCH Venture PartnersIllumina VenturesMSD Global Health Innovation Fund
Platform connecting healthcare providers with life science experts to access critical information and insights.
Co-investorsJavelin Venture PartnersMcKesson VenturesMSD Global Health Innovation FundSlater Technology FundSpectrum Equity
TransVoyant offers a supply chain intelligence engine, the CDI Physics Nucleus, that uses a physics and mathematical framework to model supply chain behavior in real time, processing large volumes of global events to calculate disruption impacts and automatically orchestrate responses.
AI & Machine LearningEnterprise SoftwareLogistics & Supply ChainAlexandria, US
Dennis Groseclose(Executive Officer, Director)Tim Fleischer(Founder)inShariar Shahidi(Executive Officer)Dawn Morat(Executive Officer)James Clautice(Executive Officer)
BoardPatrick McPherson(Director)
Co-investorsIn-Q-TelMSD Global Health Innovation Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.